Surgery for locally advanced renal cell carcinoma (RCC) may be safe for patients after neoadjuvant durvalumab +/- tremelimumab, according to the results of a phase 1b study presented at the 24th Annual Meeting of the Society of Urologic Oncology. Prior research has demonstrated the effectiveness of immune checkpoint inhibitors (ICIs) for metastatic RCC, and new studies are beginning to investigate the utility of ICIs in the neoadjuvant and adjuvant settings. Currently, the changes resulting from immune checkpoint inhibition on the renal and perinephric tissue remain unclear, and the ...
Localized Renal Cell Carcinoma
Advertisement
Latest News
Researchers evaluated biomarkers to determine their prognostic potential for determining treatment modality for ccRCC.
Patients with early-onset RCC underwent genetic testing more often than those with bilateral RCC.
A Danish study suggests that diabetes has a significant impact on OS in patients with RCC who undergo nephrectomy.
A Merit Award-winning abstract offered insight into differences in RCC susceptibility and implications for genetic screening.
The anti-PD-1 therapy met the trial’s key secondary endpoint of OS for patients with RCC following nephrectomy.
Certain risk factors can result in pathological upstaging in patients treated with nephrectomy for nonmetastatic RCC.
Advertisement
Knowledge Hub Spotlight
Curated clinical content based on conditions, therapies, and technologies
Conference Coverage
The retrospective analysis evaluated the data of patients who underwent multiagent chemotherapy.
At SUO 2023, Dr. Nicholas Corsi, UT Southwestern, presented one of the largest multinational studies on NAC in UTUC to date.
Almost half of all patients initiating 1L platinum-based chemotherapy were unable to receive maintenance avelumab treatment.
The generative AI model ChatGPT was fed a prostate cancer risk stratification algorithm.
The primary outcome was the potential for focal or hemi-gland ablation following analysis of the final pathologic specimen.
R-RPLND may offer lower morbidity and improved perioperative outcomes than O-RPLND for patients with CS II testicular cancer.
Advertisement
Advertisement
Trending
The first PET scans using Illuccix, Telix’s PSMA-PET imaging agent, have been carried out in cooperation with BAMF Health.
Nanobubbles can target membrane proteins, including PSMA, to bind to receptors that are overexpressed in cancer cells.
Few biomarkers predict therapeutic response to radiation or adjunctive treatments in PCa patients treated with radiotherapy.
